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Abstract
We introduce a new measure of antigenic distance between influenza A vaccine
and circulating strains. The measure correlates well with efficacies of the H3N2
influenza A component of the annual vaccine between 1971 and 2004, as do results
of a theory of the immune response to influenza following vaccination. This new
measure of antigenic distance is correlated with vaccine efficacy to a greater degree
than are current state-of-the-art phylogenetic sequence analyzes or ferret antisera
inhibition assays. We suggest that this new measure of antigenic distance be used
in the design of the annual influenza vaccine and in the interpretation of vaccine
efficacy monitoring.
Preprint submitted to Elsevier Science 24 October 2018
1 Introduction
Annual influenza epidemics are responsible for the deaths of 250000 to 500000
people worldwide and cause illness in 5 to 15% of the total population each year
[1]. The total direct and indirect costs associated with influenza in the USA
are roughly $10 billion [2], and the economic cost of an influenza pandemic is
estimated to be between $71–167 billion [3] in the USA alone. Vaccination is
the primary method employed to prevent infection by influenza and its asso-
ciated complications. Antigenic change, combined with the high transmission
rate of influenza strains, means that the vaccine must be redesigned annually,
currently based upon phylogenetic, experimental, and epidemiological analy-
sis.
The effectiveness of the annual influenza vaccine varies from year to year
due to changes in the identity of the circulating influenza strains. Typically,
three strains are included in the annual vaccine, with these three strains cho-
sen to be as similar as possible to those projected to be the most prominent
circulating strains in the upcoming influenza season. Currently, the vaccine
contains H3N2 and H1N1 influenza A components and an influenza B com-
ponent. Since the mutation rate of the influenza virus is rather high, vaccine
efficacies are rarely 100%, and are more typically 30 – 60%, against influenza-
like illness. As significant as the estimated worldwide mortality is, it rises
by another factor of 160% [4] to 260% [5] if influenza-induced complications
to patients with other conditions are included, and the influenza vaccine on
average significantly reduces such excess mortality [6]. Vaccine efficacy can
even be negative, however, due to original antigenic sin [7,8,9], the tendency
for antibodies produced in response to exposure to influenza vaccine antigens
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to suppress the creation of new, different antibodies in response to exposure
to new versions of the influenza virus. The efficacy of the annual influenza
vaccine, and whether original antigenic sin may occur, depends sensitively on
how similar the vaccine and circulating viral strains are. Current state of the
art measures of antigenic distance are based on ferret antisera hemagglutinin
inhibition assays [10,11,12], and these distances are assumed to correlate well
with vaccine efficacies in humans. However, to our knowledge no such good
correlation has ever been shown for an experimental or theoretical measure
of antigenic distance. In addition to its annual value, a reliable measure of
antigenic distance would provide valuable extra time if preparation and rush
production of a modified vaccine is necessary to stem the spread of a newly
emerged influenza strain [13]. We here provide a quantitative definition of the
difference between dominant epitope regions in the vaccine and circulating
strain and show that this definition of antigenic distance correlates well with
human influenza vaccine efficacy over the last 35 years.
2 Methods
Our theory models the response of an immune system not subject to im-
munosenescence. Therefore, we limited consideration to experimental studies
of vaccine efficacy for 18 to 64 year old subjects in all years since sequencing
began, when the H3N2 subtype of influenza A was the predominant virus,
and where epidemiological data on vaccine efficacy exists. We focus on the
H3N2 strain because it is the most common strain and is responsible for
significant morbidity and mortality and due to the abundance of available
crystallographic, genetic, and epidemiological data. Our approach, however, is
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general. As is customary, we restrict attention to the hemagglutinin protein,
against which neutralizing antibodies are generated [14]. Shown in figure 1 is
the hemagglutinin protein for the A/Fujian/411/2002 strain with the epitope
regions highlighted.
Our theory of the immune response to vaccination and disease uses the gen-
eralized NK model [9] to calculate affinity constant values for the immune
response to an antigen following vaccination. In this theory, the natural or-
der parameter to distinguish between the vaccine strain and the circulating
strain is the fraction of amino acids that differ in the dominant epitope region.
The model considers the diversity of an individual’s antibody repertoire and
includes interactions within the antibody and between the antibody and the
antigen. Here, the binding constant is determined as K = exp(a− bU), where
a = −18.56 and b = 1.67 are found from a comparison of the dynamics of the
model with experiment [9], and U is the energy function for an antibody [9].
To apply the theory to a candidate vaccine and circulating strain, the se-
quences and identity of the dominant epitope must be known. The sequences
and identities of the vaccine and circulating strains for each year were taken
from Ref. [15]. The definition of the five epitopes, or surface regions that are
recognized by human antibodies, in the H3N2 hemagglutinin protein were
also taken from Ref. [15]. The dominant epitope, or the epitope that induces
the most significant immune response, for a particular circulating strain in a
particular year was taken as that which had the largest fractional change in
amino acid sequence relative to the vaccine strain [16,17,18,19]. We use as our
definition of antigenic distance pepitope, where
pepitope =
number of amino acid differences in the dominant epitope
total number of amino acids in the dominant epitope
. (1)
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The difference between the vaccine strain and the circulating strain is de-
fined in the model by pepitope, eq. 1. The vaccine efficacy, E, was assumed to
correlate with the binding constant as E = α ln[Ksecondary(pepitope)/Kprimary],
where the constant α is chosen so that a perfect match between the vaccine
and circulating strain leads to 47% vaccine efficacy (which matches historical
data, see table 1), Kprimary is the binding constant for the primary immune
response, and Ksecondary is the binding constant for the secondary immune re-
sponse following vaccination. The theory is entirely predictive, with no fitted
parameters save for the determined constant α. For example, the point at
which the vaccine efficacy becomes negative is independent of the value of α.
3 Results
Shown in figure 2 and table 1 are the experimental vaccine efficacies and the
efficacies predicted by the theory as a function of pepitope. Vaccine efficacies
are taken from the literature [20,21,22,23,24,25,26,27,28,29,30,31,32,33,34] and
defined as
(u− v)/u , (2)
where u is the influenza-like illness rate of unvaccinated individuals, and v is
the influenza-like illness rate of vaccinated individuals. While the epidemiolog-
ical estimates of u and v contain statistical noise, these are the best estimates
available of vaccine efficacy in humans. The statistical mechanical model cap-
tures the essential physics of the immune response to influenza vaccination
and demonstrates the value of using pepitope to define the degree of antigenic
drift. Consideration of antigenic drift of the dominant epitope follows from
5
immunoassays and crystallographic data that show only the epitope regions
are significantly involved in immune recognition [35]. When the antigenic drift,
pepitope, in the dominant epitope is greater than 0.19, according to historical
records, or 0.22, according to theory, the vaccine efficacy becomes negative
(see figure 2). This regime is to be avoided. For example, in the 1997/1998
northern hemisphere influenza season, when the Sydney/5/97 strain became
widespread, pepitope = 0.238, and the vaccine efficacy was -18 % [29]. The only
data point that falls significantly off the theory is that for the 1989/1990 epi-
demic [36], in which it is likely that multiple circulating strains were present,
including influenza B strains [37,24].
When the vaccine efficacy is compared to the sequence difference of the entire
hemagglutinin protein,
psequence =
number of amino acid differences in the sequence
total number of amino acids in the sequence
, (3)
one current measure of antigenic drift used to construct phylogenetic rela-
tionships between circulating strains for the WHO February report [38], the
correlation is far less apparent. These data are shown in figure 3 and table 1.
Since much of the protein is inaccessible to antibodies or simply not recognized
by human antibodies, drift in much of the protein sequence is not correlated
with vaccine efficacy.
When the vaccine efficacy is compared to the antigenic distance derived from
ferret antisera [11,12], the dominant current measure of antigenic drift used to
confirm phylogenetic strain analysis [38], the correlation is again less apparent.
These data are shown in figure 4 and table 1. It appears that the ferret antisera
experiments capture no more information than does the analysis with psequence.
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A ferret-derived antigenic distance of zero does not always guarantee that the
two strains are identical. For example, for the 1996/1997 vaccine strain of
A/Nanchang/933/95 and circulating strain of A/Wuhan/359/95, the ferret-
derived antigenic distance was zero, whereas, pepitope = 0.095, and the vaccine
efficacy was 27% in the northern hemisphere [31] and 11% the next year in
the southern hemisphere [30]. These values are much lower than the average
for a perfect match between vaccine and circulating strains, which is 47%.
4 Discussion
Vaccine design is done under considerable time pressure. At present, the WHO
and national health agencies in the northern hemisphere determine the compo-
nents of the annual flu vaccine between February and April. The vaccine is then
produced by growing virus in hen’s eggs, and it is distributed in September
after regulatory tests in mid-July [39]. Data collection relating to the effective-
ness of the vaccine can begin in October, and by January a very good measure
of the season’s vaccine has been obtained. The availability of high-growth re-
assortments from egg-cultured strains imposes additional constraints on the
choice of possible vaccine strains. Given the constraints imposed by the biol-
ogy and manufacturing process, one wishes to choose the strain that provides
the best possible match to the anticipated circulating strain for the following
season.
We believe that the antigenic distance between strains would profitably be
defined by world health professionals as pepitope (figure 2), rather than as se-
quence distance (figure 3) or from ferret antisera assays (figure 4). Of impor-
tance to note is that the immune response is non-monotonic and non-linear in
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the antigenic distance, i.e. original antigenic sin or negative vaccine efficacy
exists only for an intermediate antigenic distance. In this regime, the vaccine
can induce a greater degree of susceptibility to flu-like illness in vaccinated
individuals relative to unvaccinated individuals. This negative efficacy has oc-
curred 26% of the time for circulating H3N2 strains in the last 33 years (5 of
the 19 data points in table 1, figure 2 and figure 3 are negative). Thus, original
antigenic sin can occur not only if an individual’s flu shot is not updated on
an annual basis, but also even if an individual’s flu shot is updated yearly.
The original antigenic sin regime is to be avoided both for the immunological
consequences and for the negative impact of such a vaccine on public health
policy acceptance. Our theory quantifies where the regime lies and lends ad-
ditional credence to the experimental measurements of such negative vaccine
efficacies. While negative efficacies have often been thought to be experimen-
tal error (and appear to be noise in figure 3), they are not. Negative efficacies
appear only for large values of pepitope (see figure 2).
As an example of how our theory can be used to help guide public health policy,
we apply it to the 2004/2005 northern hemisphere flu season. By using pepitope
as the definition of antigenic distance, one may be quantitative about which
strains will a priori be most protective, and so should be chosen for inclusion
in the annual vaccine. For example, to combat the A/Fujian/411/2002 strain
that was predominant in the 2003–2004 influenza epidemic, the CDC council
decided to use A/Wyoming/3/2003, a strain termed ‘antigenically equivalent’
to A/Fujian/411/2002, as the H3N2 component of the 2004–2005 vaccine [40].
Our analysis yields pepitope = 0.095 between these two strains, suggesting that
the vaccine will have an efficacy of roughly 20% for influenza-like illness against
the Fujian strain (see figure 2), and that these strains are not antigenically
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equivalent. Conversely, for A/Kumamoto/102/2002, another available H3N2
component [41], we find pepitope = 0 versus A/Fujian/411/2002, suggesting
this component would provide superior protection to Fujian than would the
Wyoming strain.
Continuing this example of how our theory can be used in vaccine design,
we show in figure 5 the calculated pepitope values and vaccine efficacies be-
tween recent influenza A H3N2 vaccine components and circulating strains.
Many isolates from the 2004/2005 flu season have been A/Fujian/411/2002-
like strains [42]. Another circulating strain that began to emerge in late 2004 is
A/California/7/2004, and an A/California/7/2004-like strain is recommended
as the influenza A component of the 2005/2006 northern hemisphere vaccine
by the WHO [43], suggesting that this is an important strain to consider as
an example. For individuals who received a vaccination in 2003/2004 (the
A/Panama/2007/99 strain) and who were not exposed to the Fujian strain,
their protection against the Fujian strain is low, and their protection against
the California strain is in the region of original antigenic sin. For individu-
als who were vaccinated in the 2004/2005 season (the A/Wyoming/3/2003
strain), their protection against the Fujian strain is moderate, but their pro-
tection against the California strain is again in the region of original antigenic
sin. For individuals who were exposed to the Fujian strain in 2003/2004 or
2004/2005, their protection against the California strain is just in the region
of original antigenic sin. The 2005 southern hemisphere vaccine strain was
A/Wellington/1/2004. Our analysis yields pepitope = 0.143 between Welling-
ton and California indicating the vaccine will provide a low level of protection
against the California strain. These findings suggest that production of a new
vaccine strain to combat A/California/7/2004 in the next flu season is essen-
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tial. Persons who recieved a flu vaccine in 2003/2004 and/or 2004/2005 should
be particularly encouraged to receive a flu shot in 2005/2006 as they are likely
to be more susceptible to this new strain than if they had not received their
flu shot in the previous 2 years.
We believe that greater resources need to be applied to the experimental study
of the efficacy of the flu vaccine each year. For example, in order to calculate
the antigenic distance optimally, the dominant human epitope in each strain
is needed, and is not currently measured. Measurement of which epitope is
dominant for each vaccine and circulating strain should increase the predictive
ability of our approach, beyond that in figure 2. More epidemiological studies
relating antigenic drift to vaccine efficacy are needed [44] and would help guide
the management of health resources during the flu season. Since substantial
costs are associated with lost work due to influenza among those in the 18-64
age bracket, large studies of this age range are both important and informative,
due to lack of immunosenescence. Continuous measurement and sequencing
of the dominant circulating strains during the flu season, combined with the
theory of figure 2, should enable better prediction of the severity of the annual
flu season and better design of the subsequent year’s vaccine.
More generally, our results have implications for the design of vaccines to com-
bat rapidly mutating viral diseases that are controlled by antibody responses.
We suggest that antigenic drift in the dominant epitope, pepitope, will provide
a prediction measure of efficacy for such vaccines. This quantitative measure
of efficacy may then be used to determine the frequency and nature of vaccine
redesign that is necessary.
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Appendix: The Generalized NK Model
Our theory of the immune response to vaccination and disease uses the gen-
eralized NK model [9] to calculate affinity constant values for the immune
response to an antigen following vaccination. In this theory, the natural order
parameter to distinguish between the vaccine strain and the circulating strain
is the fraction of amino acids that differ in the dominant epitope region, pepitope.
The model considers the diversity of an individual’s antibody repertoire and
includes interactions within the antibody and between the antibody and the
antigen. Here, the binding constant is determined asK = exp(a−b〈U〉), where
a = −18.56 and b = 1.67 are found from a comparison of the dynamics of the
model with experiment [9] and U is the energy function for an antibody and
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is defined as
U =
M∑
i=1
U sdαi +
M∑
i>j=1
U sd−sdij +
P∑
i=1
U ci . (4)
The parameters within the generalized block NK model represent the number
of secondary structures and the total size of the variable region [9]. We have
L = 5 different subdomain energy functions of the NK form
U sdαi =
1
[M(N −K)]1/2
N−K+1∑
j=1
σαi (aj , aj+1, . . . , aj+K−1) , (5)
where aj is the amino acid type of the jth amino acid in the subdomain, and
αi is the type of the ith subdomain. As in previous studies, we consider the
case where the range of the interactions within a subdomain is specified by
K = 4 and there are N = 10 amino acids in each subdomain [45]. Here σαi is
a quenched Gaussian random number with zero mean and a variance of unity,
and it is different for each value of its argument for each of the L subdomain
types, αi. The interaction energy between secondary subdomain structures is
given by
U sd−sdij =
[
2
DM(M − 1)
]1/2
×
D∑
k=1
σ
(k)
ij
(
a
(i)
j1 , . . . , a
(i)
jK/2
; a
(j)
jK/2+1
, . . . a
(j)
jK
)
. (6)
Here M = 10 is the number of antibody secondary structural subdomains. We
considerD = 6 interactions between secondary structures [45]. The zero-mean,
unit-variance Gaussian σ
(k)
ij and the interacting amino acids, j1, . . . , jK , are se-
lected at random for each interaction (i, j, k). In our model, P = 5 amino acids
contribute directly to an antigen binding event, where the chemical binding
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energy of each amino acid is given by
U ci =
1√
P
σi (ai) , (7)
where the zero-mean, unit-variance Gaussian σi and the contributing amino
acid, i, are chosen at random.
To model the immune system dynamics, we use 30 rounds of point muta-
tion and selection to evolve our antibody sequences, which corresponds to an
immune response of approximately 10 days. For each round of selection we
conduct 0.5 point mutations per antibody sequence and amplify the best 20%
of antibody sequences to form the starting population for the next round of
selection. The secondary immune response following vaccination uses evolved
memory sequences as well as naive cells, whereas the primary immune response
uses only naive cells [9].
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Strain Strain Efficacy Epitope
1971-72 Aichi/2/68 (V01085) HongKong/1/68 (AF201874) 7 % [20] A 0.158 0.033
1972-73 Aichi/2/68 (V01085) England/42/72 (AF201875) 15 % [20] B 0.190 0.055
1973-74 England/42/72 (ISDNENG72) PortChalmers/1/73 (AF092062) 11 % [20] B 0.143 0.018 5 [11] 4 [11]
1975-76 PortChalmers/1/73 (AF092062) Victoria/3/75 (ISDNVIC75) −3 % [20] B 0.190 0.055 4 [46] 16 [46]
1984-85 Philippines/2/82 (AF233691) Mississippi/1/85 (AF008893) −6 % [21] B 0.190 0.033 2 [47] 2 [47]
1985-86 Philippines/2/82 (AF233691) Mississippi/1/85 (AF008893) −3 % [22,23] B 0.190 0.033 2 [47] 2 [47]
1987-88 Leningrad/360/86 (AF008903) Shanghai/11/87 (AF008886) 17 % [22,24] B 0.143 0.024 2 [47] 1 [47]
1989-90 Shanghai/11/87 (AF008886) England/427/88 (AF204238) −6 % [24] A 0.105 0.021
1992-93 Beijing/32/92 (AF008812) Beijing/32/92 (AF008812) 59 % [25] 0.0 0.0 0 [48] 0 [48]
1993-94 Beijing/32/92 (AF008812) Beijing/32/92 (AF008812) 38 % [23] 0.0 0.0 0 [48] 0 [48]
1994-95 Shangdong/9/93 (Z46417) Johannesburg/33/94 (AF008774) 25 % [26] A 0.105 0.021
1995-96 Johannesburg/33/94 (AF008774) Johannesburg/33/94 (AF008774) 42 % [27] 0.0 0.0 0 [49,50] 0 [49,50]
1996-97 Nanchang/933/95 (AF008725) Wuhan/359/95 (AF008722) 27 % [31] B 0.095 0.006 0 [49,50] 0 [49,50]
1997 Nanchang/933/95 (AF008725) Wuhan/359/95 (AF008722) 11 % [30] B 0.095 0.006 0 [49,50] 0 [49,50]
1997-98 Nanchang/933/95 (AF008725) Sydney/5/97 (AJ311466) −18 % [29] B 0.238 0.043 4.5 [49,51] 27.3 [49,51]
1998-99 Sydney/5/97 (AJ311466) Sydney/5/97 (AJ311466) 34 % [29] 0.0 0.0 0 [38,49] 0 [38,49]
1999-00 Sydney/5/97 (AJ311466) Sydney/5/97 (AJ311466) 43 % [33] 0.0 0.0 0 [38,49] 0 [38,49]
2001-02 Panama/2007/99 (ISDNCDA001) Panama/2007/99 (ISDNCDA001) 68 % [32] 0.0 0.0 0 [38,49] 0 [38,49]
2003-04 Panama/2007/99 (ISDNCDA001) Fujian/411/2002 (ISDN38157) 12 % [34] B 0.143 0.040 2 [38] 8 [38]
Table 1. Summary of results. The table includes the identities and accession numbers of the vaccine and circulating strains for each of the
years since 1971 that the H3N2 virus has been the predominant influenza virus and for which vaccine efficacy data are available. Vaccine
efficacy is taken from the literature [20,21,22,23,24,25,26,27,28,29,30,31,32,33,34] and defined by eq. 2. Where more than one study exists
for the same influenza season, the efficacy results are averaged. The dominant epitope is predicted by our theory for all seasons where the
vaccine and circulating strains are not a match. The pepitope and psequence values are calculated using eq. 1 and eq. 3, respectively. Two
measures of antigenic distance from ferret antisera assays, d1 [11] and d2 [12], are determined from the literature [11,38,46,48,49,47,51,50].
Where more than one antisera assay has been performed, the calculated distances are averaged.
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Fig. 1. Hemagglutinin protein for the A/Fujian/411/2002 strain. Highlighted are
the A (red), B (orange), C (brown), D (green), and E (blue) epitopes [15]. The rest
of the protein is shown in ribbon format.
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Fig. 2. Vaccine efficacy for influenza-like illness as a function of pepitope
as observed in epidemiological studies and as predicted by theory. Also
shown is a linear least squares fit to the data (long dashed, R2 = 0.79).
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Fig. 3. Vaccine efficacy as observed in epidemiological studies for influenza-like ill-
ness as a function of psequence (see eq. 3). Also shown is a linear least squares fit
to the data (long dashed, R2 = 0.57). The epidemiological data shown in this
figure are the same as in figure 2. Only the definition of the x-axis is different.
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Fig. 4. Vaccine efficacy for influenza-like illness as a function of two measures of
antigenic distance, d1 [11] and d2 [12], derived from ferret antisera experiments. Ex-
perimental data were collected from a variety of sources [11,38,46,48,49,47,51,50].
Results were averaged when multiple hemagglutination inhibition (HI) studies had
been performed for a given year. These HI binding assays measure the ability of
ferret antisera to block the agglutination of red blood cells by influenza viruses.
Also shown are linear least squares fits to the d1 (long dashed, R
2 = 0.54) and
d2 (short dashed, R
2 = 0.41) data. The epidemiological data shown in this fig-
ure are the same as in figure 2. Only the definition of the x-axis is different.
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Fig. 5. pepitope (blue) and estimated vaccine efficacy (black) from figure 2 between
components used in the 2003/2004 and 2004/2005 vaccinations and circulating
strains in the 2004/2005 season.
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